

Case Report

Rapidly progressive interstitial lung disease-associated hypomyopathic dermatomyositis complicated with pneumomediastinum: A case-based review



Julio Alejandro Cerna-López^a, Paul J. Tejada-Llacsca^{a,*},
Fiorella Andrea de Jesús Valle-Farfán^a, Graciela S. Alarcón^{b,c},
Manuel F. Ugarte-Gil^{a,d}, Víctor R. Pimentel-Quiroz^{a,d}

^a Rheumatology Service, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru

^b School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA

^c School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru

^d School of Medicine, Universidad Científica del Sur, Lima, Peru

ARTICLE INFO

Article history:

Received 6 February 2021

Accepted 15 June 2021

Available online 22 July 2021

Keywords:

Anti-MDA5 antibodies

Clinically amyopathic

dermatomyositis

Spontaneous pneumomediastinum

ABSTRACT

Clinically amyopathic dermatomyositis (CADM) is associated with antibodies directed against the protein encoded by the melanoma differentiation-associated gene 5 (MDA5). CADM patients have an increased risk of developing rapidly progressive interstitial lung disease (RP-ILD) and spontaneous pneumomediastinum. Two Peruvian cases of RP-ILD-associated CADM with spontaneous pneumomediastinum are presented, one of them was anti-MDA5 antibody positive. To our knowledge, this is the first report of anti-MDA5-associated CADM in the Peruvian population.

© 2021 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Dermatomiositis hipomiotópica asociada con enfermedad pulmonar intersticial rápidamente progresiva complicada con neumomediastino: una revisión basada en casos

RESUMEN

La dermatomiositis clínicamente amiotópica (DMCA) se relaciona con anticuerpos dirigidos contra la proteína codificada por el gen asociado con la diferenciación del melanoma 5 (MDA5). Los pacientes con DMCA tienen un mayor riesgo de desarrollar enfermedad pulmonar intersticial rápidamente progresiva y neumomediastino espontáneo. Se presentan

Palabras clave:

Anticuerpo anti-MDA5

Dermatomiositis amiotópica

Neumomediastino

* Corresponding author.

E-mail address: paultejada24@gmail.com (P.J. Tejada-Llacsca).

<https://doi.org/10.1016/j.rcreu.2021.06.001>

0121-8123/© 2021 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

dos casos peruanos de DMCA asociada con enfermedad pulmonar intersticial rápidamente progresiva con neumomediastino espontáneo, uno de ellos positivo para anticuerpos anti-MDA5. Hasta nuestro conocimiento, este es el primer reporte de DMCA asociado con anti-MDA5 en la población peruana.

© 2021 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Clinically amyopathic/hypomyopathic dermatomyositis (CADM) is a rare disease which approximately represents 20% of dermatomyositis (DM) patients. Amyopathic is defined as cutaneous features of DM without muscle weakness, elevated serum muscle enzymes or abnormalities on muscle test as electromyography (EMG) or muscle biopsy. Hypomyopathic is an entity without objective weakness but may have subclinical muscle involvement on muscle enzymes, imaging, EMG or biopsy.¹ Most patients with CADM have antibodies against the protein encoded by the melanoma differentiation-associated gene 5 (MDA5). This antibody increases the risk of patients developing a rapidly progressive interstitial lung disease (RP-ILD) and spontaneous pneumomediastinum in 26- and 15-fold, respectively; these risks are higher than in patients without anti-MDA5.² Both aforementioned complications are associated with a poor prognosis^{3,4}; moreover, survival rate in CADM patients is about 40.8–45.0% by six months.⁵ We are now reporting two cases of RP-ILD-associated CADM complicated with pneumomediastinum (one of them was anti-MDA5 antibody positive) from a Latin-American (Peruvian) center.

Case 1

A 47-year-old male Mestizo patient, previously healthy, was admitted to the hospital with a three-month history of a 10 kg weight loss, diffuse alopecia, decreased proximal muscle strength in upper limbs, myalgia, fever, progressive dyspnea, and Raynaud's phenomenon. On physical examination, he was on acute respiratory distress but hemodynamically stable. Vital signs were Blood Pressure (BP): 120/70 mmHg, heart rate: 78 bpm, breathing 22 breaths per minute. He exhibited Gottron's papules over the metacarpophalangeal joints (MCPs) and knees, and a non-suppurative superficial ulcerative Gottron's on elbow. Muscle strength was 4/5 proximally and 5/5 distally in the upper extremities, and 5/5 proximally and distally in the lower extremities. His blood oxygen saturation (SpO₂) was 92%. Baseline tests were obtained: white blood cells (WBC): 4610, lymphocytes: 507, platelets: 160,000/mm³, C-reactive protein (CRP): 3.3 (0–10) mg/l, lactate dehydrogenase (LDH): 363 (120–246) U/l, creatine kinase (CK): 22 (46–271) U/l, erythrocyte sedimentation rate (ESR): 37 mm/h and ferritin levels > 1650 (28–365) ng/ml. Antinuclear antibodies (ANA), anti-double stranded DNA (anti-dsDNA) and antibodies to extractable nuclear antigens were negative (Table 1). A spirometry was performed, and it showed obstruction with a possible restrictive pattern; a chest computed tomography (CT) showed




Fig. 1 – (A) Non-specific interstitial pneumonia pattern. (B) Pneumomediastinum. (C) Follow-up after one-year.

signs of severe diffuse interstitial lung injury with non-specific interstitial pneumonia (NSIP) pattern (Fig. 1A). In addition, a bronchoscopy was performed which did not show any signs of an infection and the cultures obtained were all negative. Electromyography was performed and showed an incipient myopathic pattern in both thighs.

Due to these findings, the patient was diagnosed as having ILD-associated DM; therefore, a qualitative myopathy panel

Table 1 – Laboratory findings from the two patients.

Laboratory	Case 1	Case 2
White blood cells	4610	5130
Lymphocytes	507	872
Platelets	160,000	287,000
C-reactive protein (0–10), mg/dl	3.3	4
Lactate dehydrogenase (120–246), U/l	363	239
Creatine kinase (46–271), U/l	22	24
Erythrocyte sedimentation rate, mm/h	37	59
Ferritin, ng/ml	>1650	396
Antinuclear antibodies	Negative	Positive (titer 1/320)
Anti-dsDNA	Negative	Negative
Antibodies to extractable nuclear antigens	Negative	Anti-RNP, Anti-SS-A, Anti Ro52
Qualitative myopathy panel ^a	Anti-MDA5 positive	Negative

^a Panel include antibodies against: Mi-2 alpha, Mi-2 beta, transcription intermediary factor 1 (TIF1) gamma, melanoma differentiation-associated protein 5 (MDA5), nuclear matrix protein 2 (NXP2), SUMO activating enzyme E1 (SAE1), Ku, PM-Scl100, PM-Scl75, Jo-1, signal recognition particle (SRP), threonyl-tRNA synthetase (PL-7), alanyl-tRNA Synthetase (PL-12), glycyl-tRNA synthetase (EJ), isoleucyl-tRNA synthetase (O) and Ro-52.

was performed and anti-MDA5 antibodies were found to be positive (one band corresponds to MDA5). Methylprednisolone (MTP) pulses 1 g/d for two days then prednisone 70 mg/d were started; MTP was held due to increased dyspnea (SpO₂ 88–89%) and antibiotic therapy was initiated due to a suspected pneumonia. Despite this, dyspnea persisted, and a follow up chest CT was performed which showed pneumomediastinum (Fig. 1B). In view of these findings, intravenous immunoglobulin (IVIG) 120 g (total dose of 2 g/kg) and then intravenous (IV) cyclophosphamide (CYC) 800 mg (dose of 500 mg/m²) were started. Patient had progressive and gradual improvement completing six-monthly doses of CYC. Furthermore, prednisone was tapered to 5 mg/d. Tacrolimus 2 mg/d was started as maintenance therapy. Sixteen months after disease onset the patient remains clinically stable, has not needed supplemental oxygen and there has been significant imaging improvement per CT done one year after treatment initiation (Fig. 1C).

Case 2

A 61-year-old woman with a past medical history of hypertension and hypothyroidism, was admitted to the hospital with a four-month history of malaise, dyspnea, fatigue, 8 kg weight loss and fever. She was on acute respiratory distress but hemodynamically stable. Vital signs were BP: 110/70 mmHg,

heart rate: 130 bpm, breathing 26 breaths per minute. Physical examination revealed livedo reticularis in lower limbs; non-suppurative superficial ulcerative Gottron's papules over the MCPs, elbows and knees, the ulcerations size was around 5 mm (Fig. 2). A chest CT showed interstitial lung disease with NSIP pattern (Fig. 3A). Her ANA was positive (titer 1/320 with anti-centromere and cytoplasmic patterns) with positive profile for anti-nuclear ribonucleoproteins (RNP), anti-Sjögren's-syndrome-related antigen A (SS-A) and anti-Ro52; however, anti-dsDNA, antiphospholipid antibodies and Coombs test were negative, and the complement levels were normal. Hydroxychloroquine 200 mg/d, prednisone 20 mg/d and azathioprine 50 mg/d were started. One month later, decreased of proximal muscular strength of upper and lower limbs was evident; however, muscle enzymes levels (LDH: 239 U/l, CK: 24 U/l) and electromyography were normal. Baseline tests revealed: WBC: 5130, lymphocytes: 872, platelets: 287,000/mm³, CRP: 4.0 mg/l, ESR: 59 mm/h and ferritin levels 396 ng/ml (Table 1). Mycophenolate 2 g/d and prednisone 25 mg/d (0.5 mg/kg) were started; however, after three months, dyspnea progressed to the point that minimal efforts precipitated it. A follow up chest CT was performed and showed subcutaneous emphysema and pneumomediastinum with progression of lung infiltrates (Fig. 3B). Due to these findings, anti-MDA5-associated CADM was suspected but myopathy panel was not performed because the patient could not afford it. Monthly IV-CYC 500 mg/m² to complete six months was




Fig. 2 – Cutaneous ulcer in metacarpophalangeal joints in the right (A) and left (B) hands, also in the knee (C).




Fig. 3 – (A) Non-specific interstitial pneumonia pattern. (B) Pneumomediastinum. (C) Follow-up after one-year.

started along with two doses of Rituximab 1 g fortnightly. During the first two months of treatment, patient used supplemental oxygen at home on a prn basis. The patient gradually improved, prednisone was tapered to 7.5 mg/d and tacrolimus 2 mg/d was started as maintenance therapy by month 15th of her illness. Anti-MDA5 was assessed after one year of treatment and it was negative then. Currently, the patient is clinically stable, without need for supplemental oxygen; there has been imaging improvement after one year of treatment (Fig. 3C).

The authors have obtained written informed consent of the patients included in this study. Also, the information on the patients as noted in the manuscript does not allow their identification and is protected by confidentiality. Approval by the Ethics Committee was not required given that no experimental intervention took place.

Discussion

We report two Peruvian patients with RP-ILD-associated CADM with pneumomediastinum, one of them was associated to anti-MDA5 antibody and the other one was highly suspicious of this association due to her clinical course but could not be proven since the test was not done. To our knowledge, these are the first cases published from our country and two of the few cases published from Latin-America.⁶⁻⁹ This might be explained since very few centers can perform the myopathy panel which includes the anti-MDA5 antibody and even if available it is exceedingly expensive and may not be covered by third party payors. In our country, no hospital performs this panel and its price in the private sector is about \$800.00; for example, the case of a patient with overlap Systemic Lupus Erythematosus and Dermatomyositis syndrome who developed pneumomediastinum has been reported but unfortunately, like with our second patient, anti-MDA5 antibody could not be obtained.¹⁰

The pathogenesis of anti-MDA5-associated CADM is unknown. Recently, a linking with endothelial dysfunction has been reported, where anti-MDA5 DM patients have a higher levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), endotheline-1 (ET-1) and von Willebrand factor (vWF) than polymyositis or control patients.¹¹ On the other hand, there is a possible role for lymphocytes; a study demonstrated a decreased count of lymphocytes in Anti-MDA5 DM patients which could be explained by the transferring of lymphocytes to the lungs,¹² there is also a possible participation of activated monocytes/macrophages during the cytokine storm activation.¹³ A relationship between infection, genetic and environmental factors have also been proposed.¹⁴ Viral infection is believed to interact with MDA5, therefore there is an increase of cytokines and activation of macrophages and helper T cells. Then, this would entail cell lysis with release of MDA5. This would result in antibody production against MDA5. Genetic factors, including the role of HLA-II has been supported in a Chinese population. Environmental factors have been studied in patients from China and Japan; an association between this disease and inhabiting rural areas around South East Asia rivers has been reported. These environmental factors may trigger a cytokine storm with predominant type I interferon signature.

An uncommon complication in RP-ILD-associated CADM patients is pneumomediastinum which can be explained by two possible mechanisms. The first one suggests that pneumomediastinum might be caused by an increase of the intra-alveolar pressure in the presence of ILD resulting in the air dissecting the perivascular sheaths and into the mediastinum.¹⁵ The second mechanism suggests that pneumomediastinum might be caused by necrosis of the bronchial wall due to co-existent vasculopathy; this finding is supported by the high frequency of cutaneous vasculopathy in CADM patients.^{16,17}

As it has already been noted, the presence of anti-MDA5 in CADM patients is associated with higher risk of RP-ILD up to 16 times and with a tendency to deterioration

despite immunosuppressive treatment.¹⁸ Risk factors associated with the development of RP-ILD include high ferritin levels (>450 ng/mL), alveolar-arterial oxygen gradient levels greater than 30 mmHg, a ground-glass opacity score ≥ 2 at the level of the right middle lobe¹⁹ and the presence of anti-Ro52 antibodies.^{17,20} Furthermore, partial pressure of arterial O₂ around 62% at the first visit has been associated with poor prognosis.²¹ As to our patients, the first one had a high ferritin level and the second one had anti-Ro52 antibodies, which implies the presence of RP-ILD and worsened interstitial lung disease despite immunosuppressive treatment. It is worth noting that anti-Ro52 could be involved in the pathogenesis of this condition; in fact, as it has been proposed that the interaction between MDA5 and Ro52 induces the formation of molecular complexes and subsequently increased immunogenicity.²²

Currently, the guidelines' level evidence of about anti-MDA5-associated CADM treatment is limited to medical records review studies which have shown that combined therapy with corticosteroids plus CYC and/or a calcineurin inhibitor have the best outcomes.²³ In our cases, IVIG and CYC were chosen which have shown to work very well in refractory cases as well.²⁴ However, triple therapy with prednisolone, a calcineurin inhibitor and CYC as initial treatment has shown to improve survival.²¹ On the other hand, it has been reported that rituximab could be useful in the treatment of these patients²⁵; moreover, it is possible to test negative for the anti-MDA5 antibody after receiving this treatment.²⁶ This last assertion might explain why our second patient was anti-MDA5 negative as this antibody was assessed after treatment with CYC and rituximab have been ongoing for 12 months.

In conclusion, we report two cases of RP-ILD-associated CADM complicated with pneumomediastinum. One of these cases, to our knowledge, is the first reported of anti-MDA5-associated CADM in the Peruvian population and it is one of the few published cases from Latin-America.

Conflict of interests

The authors declare that they have no conflict of interest.

REFERENCES

- Bendewald MJ, Wetter DA, Li X, Davis MDP. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. *Arch Dermatol*. 2010;146:26-30, <http://dx.doi.org/10.1001/archdermatol.2009.328>.
- Li J, Liu Y, Li Y, Li F, Wang K, Pan W, et al. Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis. *J Dermatol*. 2018;45:46-52, <http://dx.doi.org/10.1111/1346-8138.14092>.
- Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, et al. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. *Clin Rheumatol*. 2016;35:489-93, <http://dx.doi.org/10.1007/s10067-015-3001-3>.
- Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. *Rheumatology (Oxford)*. 2012;51:1278-84, <http://dx.doi.org/10.1093/rheumatology/ker518>.
- Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. *Arthritis Care Res (Hoboken)*. 2013;65:1316-24, <http://dx.doi.org/10.1002/acr.21985>.
- Collado MV, Gargiulo M, de LA, Gomez R, Gomez G, Perez N, et al. Dermatomiositis asociada al autoanticuerpo anti-MDA5. *Medicina (Buenos Aires)*. 2018;78:360-3.
- Castro Altuna AA, Calle Delgado CA, Cadena Mosquera SR. Neumomediastino y neumotórax espontáneo en una paciente con dermatomiositis, de un caso y revisión de la literatura. *Rev Am Med Respir*. 2013;13:95-101, <http://dx.doi.org/10.36015/cambios.v14.n24.2015.215>.
- Sifuentes-Giraldo WA, García-Villanueva MJ, Gorospe L. Spontaneous pneumomediastinum complicating interstitial lung disease, associated with clinically amyopathic dermatomyositis and positive anti-MDA5 antibodies. *Rev Colomb Reumatol*. 2017;24:259-64.
- Borges IBP, Silva MG, Shinjo SK. Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (Anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis. *An Bras Dermatol*. 2018;93:517-23, <http://dx.doi.org/10.1590/abd1806-4841.20186803>.
- Vega-Villanueva KI, Berrocal-Kasay A. Subcutaneous emphysema and spontaneous pneumomediastinum in systemic lupus erythematosus and dermatomyositis overlap syndrome a case report of unusual pulmonary involvement. *J Clin Rheumatol*. 2019 Dec 3, <http://dx.doi.org/10.1097/RHU.0000000000001216>.
- He C, Chen J, Luo X, Yan B. Evaluation of biomarkers related to endothelial dysfunction: proof of vasculopathy in anti-melanoma differentiation-associated gene 5 dermatomyositis. *Clin Exp Rheumatol*. 2021;39:151-7.
- Huang W, Ren FF, Luo L, Zhou J, Huang D, Pan Z, et al. The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease. *Rheumatology (Oxford)*. 2020;59:3886-91, <http://dx.doi.org/10.1093/rheumatology/keaa266>.
- Gono T, Okazaki Y, Kuwana M. Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. *Rheumatology (Oxford)*. 2021 Apr 23;keab371, <http://dx.doi.org/10.1093/rheumatology/keab371>.
- Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. *Rheumatol Int*. 2021;41:1021-36, <http://dx.doi.org/10.1007/s00296-021-04819-1>.
- Le Goff B, Chérin P, Cantagrel A, Gayraud M, Hachulla E, Laborde F, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. *Arthritis Rheum*. 2009;61:108-18, <http://dx.doi.org/10.1002/art.24372>.
- Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. *Ann Rheum Dis*. 2000;59:372-6, <http://dx.doi.org/10.1136/ard.59.5.372>.
- Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.

- Rheumatol Int. 2019;39:1971-81, <http://dx.doi.org/10.1007/s00296-019-04398-2>.
18. Chen F, Li S, Wang T, Shi J, Wang G. Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies. *Am J Med Sci*. 2018;355:48-53, <http://dx.doi.org/10.1016/j.amjms.2017.07.013>.
19. Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. *Mod Rheumatol*. 2018;28:133-40, <http://dx.doi.org/10.1080/14397595.2017.1318468>.
20. Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. *Rheumatology (Oxford)*. 2020;1-9, <http://dx.doi.org/10.1093/rheumatology/keaa786>.
21. Motegi S, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. *Eur J Dermatol*. 2019;29:511-7, <http://dx.doi.org/10.1684/ejd.2019.3634>.
22. Hall J, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff S, et al. Anti-MDA5 associated dermatomyositis: expanding the clinical spectrum. *Arthritis Care Res (Hoboken)*. 2013;65:1307-15, <http://dx.doi.org/10.1002/acr.21992>.
23. Romero-Bueno F, Díaz del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodríguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. *Semin Arthritis Rheum*. 2020;50:776-90, <http://dx.doi.org/10.1016/j.semarthrit.2020.03.007>.
24. Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. *Clin Med Insights Circ Respir Pulm Med*. 2015;9 Suppl. 1:9-17, <http://dx.doi.org/10.4137/CCRP.M.S23313>.
25. So H, Wong VTL, Lao VWN, Pang HT, Yip RML. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. *Clin Rheumatol*. 2018;37:1983-9, <http://dx.doi.org/10.1007/s10067-018-4122-2>.
26. Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. *Br J Dermatol*. 2017;176:395-402, <http://dx.doi.org/10.1111/bjd.14882>.